Clinical Research

Angiography demonstrates a high-grade, modestly angulated stenosis (arrow) in the proximal segment of a large diagonal branch (A). Predilation performed with difficulty, and the GEC could not be advanced beyond stenosis even with “inch worming” techniques. (B). Advancement of the CrossFAST (C) beyond the proximal stent edge stenosis (a.), the position of the distal end of the outer catheter (b.), and the microcatheter tip (c.) are indicated.

Next-generation guide extension catheter delivers value during complex PCI

The CrossFAST system was successfully used to deploy multiple stents after other devices fell short. 

heart surgery surgeons

AATS wants to improve research in the field of cardiothoracic surgery

The American Association for Thoracic Surgery has announced a new partnership with the Cardiothoracic Surgical Trials Network. The groups plan on working together to address current challenges in cardiothoracic surgery research.

Newsweek ranked the 50 best heart hospitals in the world

Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial

Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.

Semaglutide, the GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic, is associated with significant health benefits for patients with type 2 diabetes and peripheral artery disease (PAD), according to a late-breaking clinical trial presented at ACC.25, the annual meeting of the American College of Cardiology (ACC).

American College of Cardiology announces late-breaking clinical trials for ACC.26

The American College of Cardiology's 2026 annual meeting will include an all-time record of 60 late-breaking clinical studies.

heart doctor cardiologist

Tenaya Therapeutics could earn up to $1.1B for new heart disease research

Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new gene therapies for the treatment of cardiovascular disease. Tenaya will receive an upfront payment of $10 million, but stands to earn much more.

Thumbnail

High-sensitivity troponin protocol most successful at freestanding EDs

Freestanding EDs demonstrated meaningful operational advantages over hospitals when using an accelerated troponin pathway. This included earlier discharges for low-risk chest pain patients.

baby parent parental leave family infant

AI spots heart and lung conditions in eye images of premature infants

The AI model showcased an ability to accurately identify signs of pulmonary hypertension in retinal images. "This opens the possibility of using a simple photograph to gain insights into a premature infant's overall health," one researcher explained.

The Relief System from Relief Cardiovascular Inc. is a first of its kind device. It incorporates a valve and sensor implant that uses AI to intelligently modulate venous pressure using hemodynamic data. The system actively adjusts flow in the inferior vena cava (IVC), which lowers venous pressure to drive durable decongestion in heart failure.

New AI-enabled heart failure implant shows early potential

The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.